Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans.

Ishita K, Stefanopoulos S, Khalil A, Cheng X, Tjarks W, Rappleye CA.

Bioorg Med Chem. 2018 May 15;26(9):2251-2261. doi: 10.1016/j.bmc.2018.01.024. Epub 2018 Feb 2.

2.

Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors.

Barth RF, Yang W, Nakkula RJ, Byun Y, Tjarks W, Wu LC, Binns PJ, Riley KJ.

Appl Radiat Isot. 2015 Dec;106:251-5. doi: 10.1016/j.apradiso.2015.06.031. Epub 2015 Jul 2.

3.

Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer.

Agarwal HK, Khalil A, Ishita K, Yang W, Nakkula RJ, Wu LC, Ali T, Tiwari R, Byun Y, Barth RF, Tjarks W.

Eur J Med Chem. 2015 Jul 15;100:197-209. doi: 10.1016/j.ejmech.2015.05.042. Epub 2015 May 27.

4.

Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans.

Khalil A, Edwards JA, Rappleye CA, Tjarks W.

Bioorg Med Chem. 2015 Feb 1;23(3):532-47. doi: 10.1016/j.bmc.2014.12.006. Epub 2014 Dec 10.

5.

Iodine monochloride facilitated deglycosylation, anomerization, and isomerization of 3-substituted thymidine analogues.

Khalil A, Ishita K, Ali T, Tiwari R, Riachy R, Toppino A, Hasabelnaby S, Sayfullin N, Oliver AG, Gallucci J, Huang Z, Tjarks W.

Nucleosides Nucleotides Nucleic Acids. 2014;33(12):786-99. doi: 10.1080/15257770.2014.945648.

6.

Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy.

Sjuvarsson E, Damaraju VL, Mowles D, Sawyer MB, Tiwari R, Agarwal HK, Khalil A, Hasabelnaby S, Goudah A, Nakkula RJ, Barth RF, Cass CE, Eriksson S, Tjarks W.

J Pharmacol Exp Ther. 2013 Nov;347(2):388-97. doi: 10.1124/jpet.113.207464. Epub 2013 Sep 4.

7.

N3-substituted thymidine bioconjugates for cancer therapy and imaging.

Khalil A, Ishita K, Ali T, Tjarks W.

Future Med Chem. 2013 Apr;5(6):677-92. doi: 10.4155/fmc.13.31. Review.

8.

Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1.

Agarwal HK, McElroy CA, Sjuvarsson E, Eriksson S, Darby MV, Tjarks W.

Eur J Med Chem. 2013 Feb;60:456-68. doi: 10.1016/j.ejmech.2012.11.041. Epub 2012 Dec 5.

9.

Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.

Hasabelnaby S, Goudah A, Agarwal HK, abd Alla MS, Tjarks W.

Eur J Med Chem. 2012 Sep;55:325-34. doi: 10.1016/j.ejmech.2012.07.033. Epub 2012 Jul 27.

10.

Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues.

Tiwari R, Toppino A, Agarwal HK, Huo T, Byun Y, Gallucci J, Hasabelnaby S, Khalil A, Goudah A, Baiocchi RA, Darby MV, Barth RF, Tjarks W.

Inorg Chem. 2012 Jan 2;51(1):629-39. doi: 10.1021/ic202150b. Epub 2011 Dec 16.

11.

Synthesis of Closo-1,7-Carboranyl Alkyl Amines.

Agarwal HK, Buszek B, Ricks KG, Tjarks W.

Tetrahedron Lett. 2011 Oct 26;52(43):5664-5667.

12.

Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.

Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ.

J Neurooncol. 2009 Dec;95(3):355-365. doi: 10.1007/s11060-009-9945-x. Epub 2009 Jul 9.

13.

Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.

Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S328-31. doi: 10.1016/j.apradiso.2009.03.030. Epub 2009 Mar 27.

PMID:
19467880
14.

Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, FlexX, Glide, and Surflex.

Tiwari R, Mahasenan K, Pavlovicz R, Li C, Tjarks W.

J Chem Inf Model. 2009 Jun;49(6):1581-9. doi: 10.1021/ci900031y.

15.

Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors.

Barth RF, Yang W, Wu G, Swindall M, Byun Y, Narayanasamy S, Tjarks W, Tordoff K, Moeschberger ML, Eriksson S, Binns PJ, Riley KJ.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17493-7. doi: 10.1073/pnas.0809569105. Epub 2008 Nov 3.

16.

Synthesis and biological evaluation of inhibitors of thymidine monophosphate kinase from Bacillus anthracis.

Byun Y, Vogel SR, Phipps AJ, Carnrot C, Eriksson S, Tiwari R, Tjarks W.

Nucleosides Nucleotides Nucleic Acids. 2008 Mar;27(3):244-60. doi: 10.1080/15257770701845238.

PMID:
18260009
17.

Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.

Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.

Clin Cancer Res. 2008 Feb 1;14(3):883-91. doi: 10.1158/1078-0432.CCR-07-1968.

18.

Quantitative subcellular imaging of boron compounds in individual mitotic and interphase human glioblastoma cells with imaging secondary ion mass spectrometry (SIMS).

Chandra S, Tjarks W, Lorey DR 2nd, Barth RF.

J Microsc. 2008 Jan;229(Pt 1):92-103. doi: 10.1111/j.1365-2818.2007.01869.x.

19.

Carboranyl thymidine analogues for neutron capture therapy.

Tjarks W, Tiwari R, Byun Y, Narayanasamy S, Barth RF.

Chem Commun (Camb). 2007 Dec 21;(47):4978-91. Epub 2007 Aug 15. Review.

PMID:
18049729
20.

Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.

Wu G, Yang W, Barth RF, Kawabata S, Swindall M, Bandyopadhyaya AK, Tjarks W, Khorsandi B, Blue TE, Ferketich AK, Yang M, Christoforidis GA, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA.

Clin Cancer Res. 2007 Feb 15;13(4):1260-8.

21.

Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.

Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ.

Bioconjug Chem. 2007 Jan-Feb;18(1):101-8.

22.

Evaluation of Bacillus anthracis thymidine kinase as a potential target for the development of antibacterial nucleoside analogs.

Carnrot C, Vogel SR, Byun Y, Wang L, Tjarks W, Eriksson S, Phipps AJ.

Biol Chem. 2006 Dec;387(12):1575-81.

PMID:
17132103
23.

Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT).

Thirumamagal BT, Zhao XB, Bandyopadhyaya AK, Naranyanasamy S, Johnsamuel J, Tiwari R, Golightly DW, Patel V, Jehning BT, Backer MV, Barth RF, Lee RJ, Backer JM, Tjarks W.

Bioconjug Chem. 2006 Sep-Oct;17(5):1141-50.

PMID:
16984121
25.

Boronated thymidine analogues for boron neutron capture therapy.

Thirumamagal BT, Johnsamuel J, Cosquer GY, Byun Y, Yan J, Narayanasamy S, Tjarks W, Barth RF, Al-Madhoun AS, Eriksson S.

Nucleosides Nucleotides Nucleic Acids. 2006;25(8):861-6.

PMID:
16901817
26.

Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer.

Narayanasamy S, Thirumamagal BT, Johnsamuel J, Byun Y, Al-Madhoun AS, Usova E, Cosquer GY, Yan J, Bandyopadhyaya AK, Tiwari R, Eriksson S, Tjarks W.

Bioorg Med Chem. 2006 Oct 15;14(20):6886-99. Epub 2006 Jul 10.

PMID:
16831554
27.

Comparative molecular field analysis and comparative molecular similarity indices analysis of boron-containing human thymidine kinase 1 substrates.

Bandyopadhyaya AK, Tiwari R, Tjarks W.

Bioorg Med Chem. 2006 Oct 15;14(20):6924-32. Epub 2006 Jul 7.

PMID:
16828556
28.

Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.

Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.

Clin Cancer Res. 2006 Jun 15;12(12):3792-802.

29.

Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy.

Wu G, Barth RF, Yang W, Lee RJ, Tjarks W, Backer MV, Backer JM.

Anticancer Agents Med Chem. 2006 Mar;6(2):167-84. Review.

PMID:
16529539
30.

3-Carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy.

Byun Y, Narayanasamy S, Johnsamuel J, Bandyopadhyaya AK, Tiwari R, Al-Madhoun AS, Barth RF, Eriksson S, Tjarks W.

Anticancer Agents Med Chem. 2006 Mar;6(2):127-44. Review.

PMID:
16529536
31.

Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature.

Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM.

Mol Cancer Ther. 2005 Sep;4(9):1423-9.

32.
33.

Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy.

Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarks W.

J Med Chem. 2005 Feb 24;48(4):1188-98.

PMID:
15715485
34.

Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.

Bandyopadhyaya AK, Johnsamuel J, Al-Madhoun AS, Eriksson S, Tjarks W.

Bioorg Med Chem. 2005 Mar 1;13(5):1681-9.

PMID:
15698786
35.

Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.

Barth RF, Yang W, Al-Madhoun AS, Johnsamuel J, Byun Y, Chandra S, Smith DR, Tjarks W, Eriksson S.

Cancer Res. 2004 Sep 1;64(17):6287-95.

36.

Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy.

Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S.

Cancer Res. 2004 Sep 1;64(17):6280-6.

37.

Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties.

Johnsamuel J, Lakhi N, Al-Madhoun AS, Byun Y, Yan J, Eriksson S, Tjarks W.

Bioorg Med Chem. 2004 Sep 15;12(18):4769-81.

PMID:
15336255
38.

The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position.

Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarks W.

Appl Radiat Isot. 2004 Nov;61(5):1125-30.

PMID:
15308203
39.

Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.

Yang W, Barth RF, Wu G, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Binns PJ, Riley K, Patel H, Coderre JA, Ciesielski MJ, Fenstermaker RA.

Appl Radiat Isot. 2004 Nov;61(5):981-5.

PMID:
15308179
40.

Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.

Barth RF, Wu G, Yang W, Binns PJ, Riley KJ, Patel H, Coderre JA, Tjarks W, Bandyopadhyaya AK, Thirumamagal BT, Ciesielski MJ, Fenstermaker RA.

Appl Radiat Isot. 2004 Nov;61(5):899-903.

PMID:
15308165
41.

The role of thymidine kinases in the activation of pyrimidine nucleoside analogues.

Al-Madhoun AS, Tjarks W, Eriksson S.

Mini Rev Med Chem. 2004 May;4(4):341-50. Review.

PMID:
15134537
42.
43.

A convenient method for the computer-aided molecular design of carborane containing compounds.

Johnsamuel J, Byun Y, Jones TP, Endo Y, Tjarks W.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3213-6.

PMID:
12951095
44.

Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy.

Stephenson SM, Yang W, Stevens PJ, Tjarks W, Barth RF, Lee RJ.

Anticancer Res. 2003 Jul-Aug;23(4):3341-5.

PMID:
12926073
45.

Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy.

Shukla S, Wu G, Chatterjee M, Yang W, Sekido M, Diop LA, Müller R, Sudimack JJ, Lee RJ, Barth RF, Tjarks W.

Bioconjug Chem. 2003 Jan-Feb;14(1):158-67.

PMID:
12526705
46.

Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.

Yang W, Barth RF, Adams DM, Ciesielski MJ, Fenstermaker RA, Shukla S, Tjarks W, Caligiuri MA.

Cancer Res. 2002 Nov 15;62(22):6552-8.

47.

Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy.

Sudimack JJ, Adams D, Rotaru J, Shukla S, Yan J, Sekido M, Barth RF, Tjarks W, Lee RJ.

Pharm Res. 2002 Oct;19(10):1502-8.

PMID:
12425468
48.

Synthesis of a small library of 3-(carboranylalkyl)thymidines and their biological evaluation as substrates for human thymidine kinases 1 and 2.

Al-Madhoun AS, Johnsamuel J, Yan J, Ji W, Wang J, Zhuo JC, Lunato AJ, Woollard JE, Hawk AE, Cosquer GY, Blue TE, Eriksson S, Tjarks W.

J Med Chem. 2002 Aug 29;45(18):4018-28.

PMID:
12190323
49.

Synthesis and biological evaluation of 3'-carboranyl thymidine analogues.

Yan J, Naeslund C, Al-Madhoun AS, Wang J, Ji W, Cosquer GY, Johnsamuel J, Sjöberg S, Eriksson S, Tjarks W.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2209-12.

PMID:
12127539
50.

A novel pH-sensitive liposome formulation containing oleyl alcohol.

Sudimack JJ, Guo W, Tjarks W, Lee RJ.

Biochim Biophys Acta. 2002 Aug 19;1564(1):31-7.

Supplemental Content

Loading ...
Support Center